Via Medica Journals
Not a member yet
55128 research outputs found
Sort by
Safety of combination therapy with olaparib and bevacizumab in the maintenance treatment of a patients with newly diagnosed ovarian cancer
Full text linkOlaparib–bevacizumab combination therapy has been included in the drug program for the maintenance treatment of patients with newly diagnosed ovarian cancer (B.50). Patients with BRCA gene mutation and/or homologous recombination deficiency (HRD) are eligible for the drug program. Both drug products have an acceptable safety profile but have so far been used separately — in monotherapy. Combination therapy appears to be an effective and safe solution and a new option for maintenance treatment of patients with advanced ovarian cancer
Does radiocolloid remain the gold standard in melanomas? New sentinel lymph node localization techniques
Full text linkMelanoma is one of the most aggressive types of cancer, which makes accurate staging crucial for determining appropriate treatment. In melanoma patients, lymph node status is the most significant predictor of survival. Sentinel lymph node biopsy (SLNB) is a minimally invasive technique that provides essential information for staging, prognosis, and identifying patients who require further treatment. SLNB involves using a radioactive tracer (Technetium-99) and lymphatic mapping with a vital blue dye, such as isosulfan blue, methylene blue, or patent blue. This procedure helps patients avoid unnecessary complete lymph node dissection (CLND) when pathological examination reveals no melanoma metastases. This review summarizes various techniques for sentinel lymph nodes (SLNs) mapping and explores emerging approaches, including indocyanine green (ICG), magnetic tracers, and 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT)
Multiple primary malignancies and cancer during pregnancy — a case of two rare consecutive conditions
Full text linkCancer during pregnancy is a rare condition involving neoplasm diagnosed during pregnancy or within a year after labor. Cancer symptoms may be masked by pregnancy symptoms, which might delay diagnosis and proper treatment. Another rare phenomenon is the occurrence of multiple primary malignancies. This is defined as the appearance of two or more unrelated neoplasms in one individual, which can be located in the same or various organs. The risk is increased due to advances in cancer treatment, resulting in a growing population of cancer survivors. Since the co-occurrence of both conditions has not been previously described, we present a rare case report of a forty-year-old female patient who received these two diagnoses. The patient with a colorectal cancer family history in her third pregnancy suffered from painful lesions located in the anal area diagnosed as hemorrhoids. In the next pregnancy, the symptoms were not resolved, and the in-depth diagnosis revealed colorectal cancer. The treatment included chemotherapy during pregnancy and radical surgery involving rectum amputation in the post-partum period. Postoperative magnetic resonance imaging (MRI) revealed a fluid lesion located near the posterior vaginal wall. The cyst’s enlargement was observed in the following months, raising oncological concerns. The patient underwent a laparotomy, during which an intraoperative histopathological examination found mucinous endometrioid adenocarcinoma. Optimal cytoreduction was performed, and the patient received post-surgery chemotherapy. The tests performed did not indicate the genetic background of either neoplasm. This case suggests the need for increased oncological vigilance in cancer survivors, as well as pregnant patients
Problematyka bólów w klatce piersiowej w warunkach Podstawowej Opieki Zdrowotnej
No full textChest pain is a common reason for primary care visits and requires the exclusion of potentially life-threatening cardiac conditions. History taking, physical examination, and 12-lead electrocardiogram (ECG) form the cornerstone of differential diagnosis in ambulatory settings, enabling initial identification of cardiac emergencies. Patients presenting with chest pain of unknown etiology should be evaluated for cardiovascular risk factors. The clinical presentation of acute coronary syndrome may vary by gender, with women often exhibiting nonspecific symptoms. Patients diagnosed with angina pectoris require urgent implementation of secondary prevention strategies for myocardial ischemia. Management of chest pain in patients with elevated cardiovascular risk should integrate primary care with cardiological diagnostics, necessitating close collaborati on to ensure continuous monitoring and improved long-term prognosis.Bóle w klatce piersiowej stanowią częstą przyczynę wizyt w gabinecie lekarza rodzinnego i wymagają wykluczenia potencjalnie groźnych dla życia kardiogennych przyczyn zgłaszanych dolegliwości. Wywiad lekarski, badanie pr zedmiotowe i 12-odprowadzeniowy elektrokardiogram (EKG) stanowią podstawę diagnostyki różnicowej bólu w klatce piersiowej w warunkach ambulatoryjnych i pozwalają na wstępną identyfikację stanów zagrożenia życia o etiologii kardiologicznej. Pacjenci zgłaszający dolegliwości bólowe w klatce piersiowej o nieznanej przyczynie wymagają oceny współwystępowania czynników zwiększonego ryzyka sercowo-naczyniowego. Obraz kliniczny ostrego zespołu wieńcowego może się różnić w zależności od płci pacjenta i w szczególności u kobiet może manifestować się w postaci niespecyficznych objawów. Chorzy z rozpoznaniem dławicy piersiowej wymagają pilnego wdrożenia profilaktyki wtórnej niedokrwienia mięśnia sercowego. Postępowanie związane z dolegliwościami bólowymi w klatce piersiowej u pacjentów z po dwyższonym ryzykiem sercowo-naczyniowym powinno łączyć elementy podstawowej opieki zdrowotnej z diagnostyką kardiologiczną i wymaga ścisłej współpracy lekarskiej w celu zapewnienia pacjentom stałej kontroli i poprawy rokowania odległego
Unloading the left ventricle and unlocking transplant options: Impella 5.5 in advanced heart failure with pulmonary hypertension
No full textUsing information and communication technologies to improve awareness of early diagnosis of cancers in women
No full textDevelopments in the field of technology affect all areas of life, as well as the field of communication and information sharing to an expanding degree. These developments are directly affected by health education and raising health awareness. This study aims to draw attention to the importance of using developing technologies in professional midwifery practices in creating early diagnosis awareness about women's cancers that affect the health of women, and to provide examples of their use. Although the prevalence of cancer is gradually increasing, according to future projections, it is estimated that 27 million diagnoses will be added every year by 2030, 17 million individuals will lose their lives as a result of cancer annually and 75 million people will struggle to survive with cancer. Women are especially affected by gynecological cancers. While cervix, uterus, and ovarian cancers are among the most common cancers among women all over the world, in our country this order is listed as endometrium, ovary, and cervix cancer. Awareness of early diagnosis practices plays a major role in successfully treating the disease and improving the quality of life. Health education and consultancy practices form the basis of creating health awareness. Today's information and communication technologies, written communication tools, audio communication tools, and visual communication tools have an important place in reaching large populations. The methods within this scope are grouped under three headings: Mobile Health, Web-Based Education and Social Media Platforms. Although studies on the subject are limited, it is emphasized that health education and counseling programs implemented with technology-oriented methods are effective in raising awareness of early diagnosis practices. It is thought that the effectiveness of studies and practice in this field will increase with changing and developing technologies and the interest of a new generation of professional midwives using technology
Tamoxifen-induced hepatotoxicity and symptomatic tarlov cyst in a breast cancer survivor — coexistence or consequence?
No full textInvasive breast carcinoma is among the most prevalent malignancies affecting women globally. This case presents a 47-year-old female diagnosed with invasive breast carcinoma, treated with mastectomy, chemotherapy, targeted therapy, and hormonal therapy. During follow-up, she developed hepatic dysfunction attributed to tamoxifen and subsequently experienced lower back pain due to a Tarlov cyst. The case underscores the importance of comprehensive and sustained surveillance in breast cancer survivors for the early detection and management of treatment-related complications and musculoskeletal manifestations
Stage IV lung adenocarcinoma — complete response and long-term survival
No full textThe article presents the case of a 52-year-old patient (currently 61 years old) diagnosed with stage IIa non-smallcelladenocarcinoma of the left lung. The patient underwent surgical resection with negative margins (R0) andreceived adjuvant chemotherapy with cisplatin and vinorelbine (PN regimen). One year later, a relapse occurredwith a solitary brain metastasis, indicating disease progression to stage IV. Stereotactic radiotherapy using theGamma Knife technique was performed, followed by systemic treatment with cisplatin and gemcitabine (PGregimen), which was discontinued due to poor tolerance. Subsequently, an immunotherapy with nivolumab wasadministered and complete response was achieved after 51 treatment cycles. As of the date of publication, norecurrence has been observed, with the patient remaining in remission for six years. He is professionally active,reports no symptoms, and continues outpatient follow-up. This case highlights the importance of personalizedtherapy, the critical role of clinical trials in expanding treatment options for oncology patients, and the growingsignificance of immunotherapy in the management of advanced non-small-cell lung cancer
Drug-induced immune hemolytic anemia — the influence of selected drugs on immunohematology testing
No full textDrug-induced immune hemolytic anemia is a rare condition. It is difficult to distinguish from hemolytic anemias of other etiologies, which delays diagnosis and treatment. In cases of a positive direct antiglobulin test and negative elution results, the influence of a drug should be considered. A thorough clinical history is crucial to exclude other causes of anemia. This paper discusses the mechanism, diagnostic tests, and treatment of drug-induced hemolytic anemia. Examples of drugs most commonly reported as causes of anemia are also presented